Potassium Ion

Potassium Ion

SCHEMBL527016

CN(C)c1cccc([O-])c1.[K+]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
TSHR P16473 3/20 0.52
HSD17B10 Q99714 2/20 0.39
ALOX15 P16050 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA9 Q16790 1/20 0.39
NOTUM Q6P988 2/20 0.38
APP P05067 2/20 0.37
TERT O14746 1/20 0.37
GSK3B P49841 1/20 0.37
MAPT P10636 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
GFER P55789 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9091839 0.95 ALDH1A1 (0.52) ALDH1A1TSHRHSD17B10ALOX15CA12
Lithium Ion SCHEMBL3293326 0.95 ALDH1A1 (0.52) ALDH1A1TSHRHSD17B10ALOX15CA12
SCHEMBL4391221 0.79 ALDH1A1 (0.67) ALDH1A1TSHRHSD17B10ALOX15CA12
Potassium Ion SCHEMBL11691029 0.79 ALDH1A1 (0.37) ALDH1A1TSHRCA12CA2CA9
Trifluoromethanesulfonic Acid SCHEMBL7086264 0.78 GPR3 (0.40) ALDH1A1TSHRCA12CA1CA2
Trifluoromethanesulfonic Acid SCHEMBL7086263 0.77 ALDH1A1 (0.41) ALDH1A1TSHRCA12CA1CA2
SCHEMBL487064 0.73 ALDH1A1 (0.54) ALDH1A1TSHRHSD17B10ALOX15CA12
SCHEMBL30602821 0.72 ALDH1A1 (0.58) ALDH1A1TSHRHSD17B10ALOX15NOTUM
Lithium Ion SCHEMBL11690060 0.71 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10ALOX15TERT
SCHEMBL11691550 0.71 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10ALOX15TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9035070-B2 Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors Esteve Química, S.A. (ES) 2015-05-19 US disclosed
EP-2598469-B1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS ESTEVE QUÍMICA S A (ES) 2014-07-23 EP disclosed
US-20130184472-A1 Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors ESTEVE QUIMICA, S.A. (ES) 2013-07-18 US disclosed
EP-2598469-A1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS Esteve Química, S.A. (ES) 2013-06-05 EP disclosed
EP-2418192-A1 Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors Esteve Química, S.A. (ES) 2012-02-15 EP disclosed
WO-2012013755-A1 PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS Esteve Química, S.A. (ES) 2012-02-02 WO disclosed
US-4055523-A FIRE RETARDANT ARMSTRONG CORK COMPANY (US) 1977-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184472-A1 Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors SIGMAR1, OPRK1, OPRM1 ALDH1A1 1130/4885TSHR 108/4885HSD17B10 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.